We are live on
!
Find out more
Vanda Pharmaceuticals
VNDA
VNDA
88 hedge funds and large institutions have $187M invested in Vanda Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 88 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
296% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $3.89M
Holders
88
Holders Change
+88
Holders Change %
–
% of All Funds
2.87%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
88
Increased
–
Reduced
–
Closed
–
Calls
$15.4M
Puts
$3.89M
Net Calls
+$11.5M
Net Calls Change
+$11.5M
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GGHC
76
Gilder Gagnon Howe & Co
New York
| $91K | +$75.9K | +11,264 | New |
|
|
AAP
77
Ardsley Advisory Partners
Stamford,
Connecticut
| $81K | +$67.3K | +10,000 | New |
|
|
FANJ
78
Financial Architects (New Jersey)
Marlton,
New Jersey
| $80K | +$67.3K | +10,000 | New |
|
79
Barclays
London,
United Kingdom
| $76K | +$63.5K | +9,429 | New |
|
|
SO
80
STRS Ohio
Columbus,
Ohio
| $72K | +$59.9K | +8,900 | New |
|
81
Citigroup
New York
| $21K | +$16.9K | +2,507 | New |
|
82
Ameriprise
Minneapolis,
Minnesota
| $17K | +$14.8K | +2,197 | New |
|
|
EWM
83
Edge Wealth Management
New York
| $16K | +$13.5K | +2,000 | New |
|
84
BlackRock
New York
| $7K | +$6.11K | +907 | New |
|
85
Wells Fargo
San Francisco,
California
| $4K | +$3.72K | +552 | New |
|
|
PFG
86
Piershale Financial Group
Barrington,
Illinois
| $1K | +$680 | +101 | New |
|
87
First Manhattan
New York
| $1K | +$1.35K | +200 | New |
|
|
TRCT
88
Tower Research Capital (TRC)
New York
| – | +$189 | +28 | New |
|
VNDA Hedge Fund Activity: Q2 2013 in Review
88 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2013, worth a combined $187M.
Buyers outnumbered sellers: 88 funds opened new VNDA positions and 0 closed out — a net gain of 88 holders — while 0 added to existing stakes and 0 trimmed.
- 88 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $187M of Vanda Pharmaceuticals stock for Q2 2013.
- 88 funds opened new Vanda Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +88 holders.
Based on aggregated 13F filings for Q2 2013.